<div id="readability-page-1"><div><p>Prosus (ENXTAM:PRX) is in focus after the company reported the passing of Steve Pacak, its independent non executive director and chair of the audit and risk committees, prompting fresh attention on board oversight and governance.</p> <p>See our latest analysis for Prosus.</p> <p>Prosus shares trade at €40.65, with a 30 day share price return of 5.39% but a 90 day share price return decline of 18.32%. The 3 year total shareholder return of 34.51% contrasts with a flat 1 year outcome and suggests momentum has recently cooled despite a stronger longer term record.</p> <p>If this governance update has you reviewing your portfolio, it could be a good moment to broaden your search and check out 97 top founder-led companies</p> <p>With Prosus shares at €40.65 after a 24% year-to-date decline but a 3-year total return of 34.51%, it is worth asking whether sentiment has swung too far or whether the market is already pricing in future growth.</p> <h2>Most Popular Narrative: 49.2% Undervalued</h2> <p>Prosus's most followed narrative puts fair value at about €79.99, almost double the last close of €40.65. This frames a very optimistic upside story.</p> <blockquote> <p><em>The company's strong execution in integrating and scaling cross-segment ecosystem &#34;flywheels&#34;, particularly in Latin America and India, positions it to replicate the outsized multi-business success seen with dominant regional peers. This implies the potential to double or triple addressable revenue and materially increase operating leverage over the next several years.</em></p> </blockquote> <p><em>Read the complete narrative.</em></p> <p>Curious what justifies that kind of gap between price and fair value? The narrative leans heavily on rapid revenue expansion, fatter margins and a richer future earnings multiple. The exact mix of these assumptions matters a lot for any view on Prosus.</p> <p><strong>Result: Fair Value of €79.99 (UNDERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, this optimistic view still hinges on Tencent concentration and tougher regulatory scrutiny not eroding Prosus's earnings power or constraining future portfolio moves.</p> <p>Find out about the key risks to this Prosus narrative.</p> <h2>Another Angle on Valuation</h2> <p>The bullish narrative leans on future earnings and margin assumptions, but our DCF model points the other way, with an estimate of €28.10 compared with the current €40.65. That flags Prosus as overvalued on this measure, so which story do you lean on when pricing risk?</p> <p>Look into how the SWS DCF model arrives at its fair value.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/24203e4a-29de-4fa8-8772-68e8fbc8d9c0/chart/dcf/query-ZGF0ZT0yMDI2LTA0LTMw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/24203e4a-29de-4fa8-8772-68e8fbc8d9c0/chart/dcf/query-ZGF0ZT0yMDI2LTA0LTMw"/><figcaption>PRX Discounted Cash Flow as at Apr 2026</figcaption></figure><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Prosus for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 237 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2>Next Steps</h2> <p>Mixed messages on value and risk so far? Use that tension as a prompt to look through the data now and decide where you stand, then weigh those signals against the 5 key rewards and 1 important warning sign</p> <h2>Looking for more investment ideas?</h2> <p>If Prosus has sharpened your thinking, do not stop here. Fresh opportunities often show up where you are not currently invested.</p> <ul> <li>Spot potential value candidates early by scanning screener containing 566 high quality undiscovered gems before others catch on.</li> <li>Strengthen the quality of your holdings by checking companies in the solid balance sheet and fundamentals stocks screener (385 results) that match your risk comfort.</li> <li>Build dependable income streams by reviewing the 484 dividend fortresses and seeing which yields fit your goals.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

PROSF

TCEHY

TCTZF

<p>Prosus (ENXTAM:PRX) is under scrutiny following the death of board member Steve Pacak, raising concerns about governance. The stock trades at €40.65, reflecting a 24% decline this year, yet a 3-year total return of 34.51%. Analysts suggest the fair value is €79.99, indicating potential undervaluation, while a DCF model estimates it at €28.10, suggesting overvaluation. The contrasting views highlight the uncertainty surrounding Prosus's future growth and risks, particularly related to Tencent and regulatory challenges. Investors are encouraged to explore other opportunities and assess their portfolios accordingly.</p>

- Prosus is in the spotlight following the death of Steve Pacak, its non-executive director, raising concerns about board governance.  
- Shares currently trade at €40.65, with mixed performance data indicating a 30-day gain of 5.39% and a 90-day decline of 18.32%.  
- Analysts peg fair value at €79.99, suggesting significant upside potential, but contrasting DCF valuations indicate it may be overvalued at €28.10, highlighting differing investment perspectives.

Simplywall

A Look At Prosus (ENXTAM:PRX) Valuation After The Passing Of Key Board Member Steve Pacak